摘要
布鲁氏菌病是世界范围内最常见的人畜共患疾病,也是世界上常见的公共卫生问题。不仅严重危害人民身体健康,而且也严重影响畜牧业的发展,还会带来食品安全隐患。实践证明,疫苗免疫是预防传染病流行的最有效措施,流产双歧杆菌疫苗104M是我国唯一可用于预防人类布鲁氏菌病的疫苗。虽然流产双歧杆菌104M基因组已完全测序,但基因组注释目前尚未完成。此外,其残留毒性和疫苗诱导免疫保护的主要机制尚未阐明。本文主要阐述布鲁氏菌病的临床表现、治疗以及疫苗相关研究进展。
Brucellosis is the most common zoonotic disease and a common public health problem worldwide.It not only greatly harms the health of people,but also seriously affects the development of animal husbandry,and it also brings food safety risks.Practice has shown that vaccine immunization is the most effective measure to prevent the epidemic of infectious diseases,and Bifidobacterium abortus vaccine 104M strain is the only vaccine that has been approved for preventing human brucellosis in China.Although the 104M genome of Bifidobacterium abortus has been fully sequenced,genome annotation has not been completed at the moment.In addition,the main mechanisms of residual toxicity and vaccine-induced immune protection have not been clarified.This article mainly elaborates on the clinical manifestations and treatment of brucellosis and related research advances in vaccines.
作者
安纪红
杜田田
王占国
AN Jihong;DU Tiantian;WANG Zhanguo(Department of Infectious Diseases,Inner Mongolia Autonomous Region People’s Hospital,Hohhot 010000,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2023年第8期2012-2016,共5页
Journal of Clinical Hepatology
